DUBAI, UAE, /PRNewswire/ -- As per the latest study by ESOMAR-certified consulting firm FMI, the global biopsy devices market is estimated to surpass US$ 1862.5 million by 2021. In response to the rapidly improving healthcare infrastructure in developing economies and increasing demand for minimally invasive surgeries, the market for biopsy devices is projected to grow at a CAGR of 5.2% during the forecast period 2021 to 2031.
Rising burden of diseases such as lung cancer, breast cancer, leukemia, and others across the globe is accelerating the growth of the market. According to the American Cancer Society, approximately 1.9 million new cases of cancer are likely to be diagnosed in the U.S., out of which 608,570 of patients are predicted to succumb in the year 2021.
Thus, the demand for effective diagnostic procedures will rise as patients and their families look for advanced healthcare solutions for the treatment of cancer.
Increasing number of initiatives undertaken by governments and healthcare organizations concerning cancer diagnosis and treatment will facilitate the growth of the market. Driven by the rising healthcare expenditure and progressive research and development (R&D) activities, the market is projected to reach a valuation of US$ 3.08 Bn by the end of 2031.
As per FMI, North America is expected to lead the global biopsy device market. Supported by the rising prevalence of cancer in countries such as the U.S. and Canada, the region is estimated to account for around 34% of the market share in 2021.
"Rising discretionary funding for cancer research, growing government expenditure for upgrading healthcare infrastructure, and implementation of favorable reimbursement policies will collectively propel the growth of the global biopsy device market," says the FMI analyst.
Key Takeaways from FMI's Biopsy Devices Market Survey
- The U.S. is expected to lead the North America market, favored by the presence of favorable reimbursement scenarios in the country.
- Germany is anticipated to hold around 28% of the Europe market share, owing to the growing healthcare expenditure and extensive R&D activities.
- China is projected to account for the highest share in the Asia Pacific biopsy devices market, due to the high patient pool of cancer.
- Japan and South Korea is forecast to cumulatively account for nearly 8.4% of the global market share in 2021.
- Based on product type, the biopsy needles segment is predicated to create an absolute dollar ($) opportunity of US$ 30 million in 2021.
Key Drivers
- Rising prevalence of fatal diseases such as breast cancer and leukemia is fueling demand for biopsy devices.
- Increasing consumer preference towards minimally invasive procedures is spurring sales of biopsy devices.
- Rapid technological advancements such as ultrasound-guided biopsies and 3D optical biopsies is driving the market.
Competitive Landscape
As per FMI, the global biopsy device market is highly fragmented and around 69% of the global share is contributed by Dickinson and Company, CR Bard, Becton, B. Braun, Argon Medical Inc., Melsungen AG, Hologic, Inc, Devicor Medical Products Inc. and Cook Medical.
Leading companies in the market are focusing to developing new products and gaining regulatory approvals. Some of the players are adopting expansion strategies such as collaboration, mergers, partnership, and acquisitions to maintain their lead in the landscape. For instance,
- In 2021 Biocept, Inc., a commercial-stage cancer diagnostics company, announced entering into collaboration with an American clinical laboratory, Quest Diagnostics to offer laboratory testing services to patients in Quest for its Target Selectortm NGS-based liquid biopsy targeted lung cancer panel.
- In October 2020, GE Healthcare, a subsidiary of American multinational conglomerate General Electric incorporated, announced launching its new Serena Bright biopsy technology in the U.S. It is particularly designed to offer advanced breast cancer diagnosis and treatment.
Some of the prominent players operating in the biopsy device market profiled by FMI are:
- Argon Medical Devices, Inc.
- B. Braun Melsungen AG
- Becton Dickinson and Company
- Boston Scientific Corporation
- Cardinal Health, Inc.
- Cook Medical, Inc.
- Danaher Corporation
- Fujifilm Holdings Corp.
- Hologic, Inc.
- Medtronic plc.
More Insights on FMI's Biopsy Devices Market Study
The latest market study on the biopsy device market by Future Market Insights gives a detailed segmentation for the forecast period of 2021-2031. In order to gain a better perspective of the global biopsy device market potential, its growth, trends, and opportunities, the market is segmented on the basis of:
By Product Type:
- Guidance System
- Stereotactic X-Ray Guided Biopsy
- Ultrasound Guided Biopsy
- MRI Guided Biopsy
- Needles
- Core Needles
- Fine Aspiration Needles
- Guns
- Reagents and Kits
- Others (Brushes, Curettes and Punches etc.)
By Application:
- Medical Diagnosis
- Scientific Research
By End Use:
- Hospital
- Specialised Oncology Centres
- Diagnostic Centres
- Research Institutes
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- MEA
Key Questions Covered in Biopsy Devices Market Report
- The report offers detailed insights into biopsy device market demand outlook for 2021-2031
- The market study also highlights projected sales growth for biopsy device market between 2021 and 2031
- Biopsy device market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Biopsy device market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others.
-Ends-
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact:
Abhishek Budholiya
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/
Report: https://www.futuremarketinsights.com/reports/biopsy-device-market
Press Release Source: https://www.futuremarketinsights.com/press-release/biopsy-device-market
SOURCE Future Market Insights
CONTACT: +1-347-918-3531 / + 44 (0) 20 7692 8790
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
